Israeli court approves Chemomab repurchase of 582,023 ADSs from co-founders

Chemomab Therapeutics Ltd.

Approved repurchase of up to 582,023 ADSs for approx. $1,213,400 to help co-founders pay tax.
Tax liability stems from merger deferral that expires March 16, 2023.
Repurchase at market price to avoid bulk sales that could depress CMMB ADS price.
Company says cash runway unchanged, expected through end of 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.